New pill targets genetic driver in advanced cancers
NCT ID NCT05886920
Summary
This early-stage study is testing a new oral medication called D3S-002 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to find a safe dose, see how the body processes the drug, and look for early signs that it might help control the cancer. The study is for people whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH MAPK PATHWAY MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
D3 Bio Investigative Site
Detroit, Michigan, 48202, United States
-
D3 Bio Investigative Site
New York, New York, 10029, United States
-
D3 Bio Investigative Site
Blacktown, New South Wales, 2148, Australia
-
D3 Bio Investigative Site
Bedford Park, South Australia, 5042, Australia
-
D3 Bio Investigative Site
Nedlands, Western Australia, 6009, Australia
-
D3 Bio Investigative Site
Beijing, Beijing Municipality, 100142, China
-
D3 Bio Investigative Site
Guangzhou, Guangdong, 510080, China
-
D3 Bio Investigative Site
Harbin, Heilong Jiang, 150081, China
-
D3 Bio Investigative Site
Shanghai, Shanghai Municipality, 201801, China
-
D3 Bio Investigative Site
Hangzhou, Zhejiang, 310009, China
Conditions
Explore the condition pages connected to this study.